Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.
相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2017
已完成
1
50.0%
招募中
1
50.0%
暂无批准数据
- Hoth Therapeutics revealed preclinical data showing GDNF outperformed semaglutide in weight stabilization, glucose tolerance, and liver weight reduction in female mouse models. - GDNF attenuated weight gain by 10-15% in female mice on high-fat diets while semaglutide showed no significant impact in the same population. - The company positions GDNF as a potential game-changer in the $200 billion obesity market, offering differentiated mechanisms to address GLP-1 agonist limitations. - Hoth plans to accelerate GDNF toward IND-enabling studies with clinical trials targeted for 2027.
- Hoth Therapeutics' HT-001 achieved 100% clinical response in cancer patients receiving EGFR inhibitor therapy, with all evaluable patients reaching low-severity disease status by Week 6. - The CLEER-001 trial demonstrated a 50% reduction in disease severity using the ARIGA scale, alongside 34% improvement in oncology toxicity and 37% reduction in patient-reported pruritus. - Results showed rapid onset of improvement as early as Week 3 with sustained benefits through Week 6, highlighting HT-001's potential as supportive care for cancer patients on EGFR inhibitors.
- Hoth Therapeutics received patent approval from China National Intellectual Property Administration for its HT-KIT cancer program, covering technology designed to induce cancer cell apoptosis. - The patent protects systems and methods for targeting KIT signaling pathways to trigger programmed cell death, expanding protection in one of the world's largest oncology markets. - HT-KIT leverages splice-switching and molecular targeting strategies aimed at selectively impacting disease-relevant cells while avoiding broader systemic toxicity. - Patent protection in China enhances future partnering, licensing, and strategic transaction opportunities for the precision oncology therapeutic.
- Hoth Therapeutics reports strong safety profile for HT-001 in Phase 2 CLEER-001 trial targeting EGFR-inhibitor-associated rash with no dose-limiting toxicities observed. - The company's HT-KIT program for mastocytosis has received FDA Orphan Drug Designation and is progressing toward IND submission in 2026. - A newly launched GDNF-based metabolic program targeting obesity and hepatic steatosis has initiated studies with the Atlanta VA Medical Center. - The pipeline includes HT-ALZ for Alzheimer's disease advancing through GLP development with positive pharmacokinetic and CNS-penetration modeling.
- Hoth Therapeutics' antisense oligonucleotide HT-KIT demonstrated over 80% reduction in KIT expression and triggered significant tumor cell death within 24 hours in preclinical models of gastrointestinal stromal tumors and systemic mastocytosis. - The therapy showed no off-target toxicity across critical organs including liver, kidneys, spleen, bone marrow, and thymus in multi-dose in vivo studies. - GLP-validated bioanalytical results exceeded regulatory standards with 90.5% of reanalysis values within acceptable limits and 37-day serum stability at -80°C. - The company plans to submit an IND application in early 2026 and initiate Phase 1 trials for this precision oncology candidate targeting KIT-driven cancers.
- Hoth Therapeutics and Silo Pharma announced a 50/50 joint venture to develop a first-in-class obesity treatment based on GDNF technology exclusively licensed from the U.S. Department of Veterans Affairs. - The therapeutic platform targets the $100+ billion global obesity market and focuses on treating obesity, non-alcoholic fatty liver disease, and type 2 diabetes using VA-invented biologic technology. - GDNF has demonstrated anti-obesity effects and metabolic regulation in preclinical models, with the technology protected under U.S. Patent No. 10,052,362. - The partnership aims to address the epidemic-level obesity crisis affecting over 40% of U.S. adults, particularly veterans who are disproportionately impacted by metabolic disorders.
- Hoth Therapeutics received Japan Patent No. 7677628 for its HT-KIT platform, providing exclusive protection until August 27, 2039. - The patented technology uses splice-switching oligonucleotides to selectively disrupt KIT gene expression in mast cells implicated in chronic hives and rare cancers. - The patent positions HT-KIT for orphan indications and expedited regulatory pathways, with potential applications in mast cell-driven inflammatory and oncologic conditions. - The company sees strategic licensing opportunities across Asia as it advances this novel therapeutic platform.
- Hoth Therapeutics has received an official Filing Receipt from the USPTO for a new patent application related to its lead clinical asset HT-001, which treats dermatologic side effects in cancer patients undergoing EGFR inhibitor therapy. - The company has simultaneously filed amended claims for its HT-KIT antisense oligonucleotide technology targeting MS4A6A and FcεRIβ genes, enhancing protection for this novel therapeutic platform for allergic and inflammatory conditions. - Hoth has initiated a GLP-compliant 4-week intravenous toxicity study for HT-KIT in mice, marking significant progress toward regulatory filings and potential clinical trials.
- Hoth Therapeutics' Alzheimer's candidate HT-ALZ demonstrated significant cognitive improvements and reduced neuroinflammation in preclinical mouse models, targeting astrocyte-driven inflammation through NK-1 receptor antagonism. - Acute treatment with HT-ALZ achieved approximately 15% reduction in brain interstitial fluid amyloid-beta levels within hours, showcasing its dual mechanism addressing both pathology and symptoms of Alzheimer's disease. - The orally bioavailable compound crosses the blood-brain barrier and has an established safety profile, positioning it as a promising first-in-class therapy for early-stage Alzheimer's as the company prepares for clinical development.
- Hoth Therapeutics plans to submit an Expanded Access application for HT-001, a novel therapy targeting dermatological side effects in cancer patients receiving EGFR inhibitor treatments. - The "compassionate use" program would allow eligible patients with serious conditions to access HT-001 outside of clinical trials while the company continues to gather safety and efficacy data. - Positive progress in ongoing clinical studies has prompted this initiative, which aims to address a significant unmet need affecting quality of life for cancer patients undergoing targeted therapies.
